BioAge Labs (BIOA) Profit After Tax (2023 - 2026)
BioAge Labs' (BIOA) quarterly Profit After Tax came in at -$26.6 million in Q2 2026, down 23.28% year-over-year from -$34.7 million in Q2 2025, and down 19.75% quarter-over-quarter from -$22.3 million in Q1 2026.
Analysis
BioAge Labs (BIOA) Profit After Tax (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Profit After Tax across 4 years of filings, most recently posting -$26.6 million for Q2 2026.
- In Q2 2026, Profit After Tax fell 23.28% year-over-year to -$26.6 million; the TTM figure through Jun 2026 stood at -$95.0 million (down 20.15% YoY), while the FY2025 annual figure was -$80.6 million, down 13.35% from the prior year.
- Profit After Tax came in at -$26.6 million for Q2 2026 at BioAge Labs, down from -$22.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$12.9 million in Q1 2025 to a low of -$26.6 million in Q2 2026.
- Average Profit After Tax over 4 years is -$19.7 million, with a median of -$21.0 million recorded in 2023.
- Year-over-year, Profit After Tax advanced 13.82% in 2025 and sank 72.13% in 2026.
- Over 4 years, Profit After Tax stood at -$21.0 million in 2023, then fell by 0.8% to -$21.1 million in 2024, then slipped by 22.78% to -$25.9 million in 2025, then slipped by 2.72% to -$26.6 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$26.6 million in Q2 2026, -$22.3 million in Q1 2026, and -$25.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn | -26.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.65 Mn |
| Mar 31, 2026 | -22.25 Mn |
| Dec 31, 2025 | -25.94 Mn |
| Sep 30, 2025 | -20.17 Mn |
| Jun 30, 2025 | -21.62 Mn |
| Mar 31, 2025 | -12.93 Mn |
| Dec 31, 2024 | -21.13 Mn |
| Sep 30, 2024 | -23.41 Mn |
| Jun 30, 2024 | -13.58 Mn |
| Mar 31, 2024 | -12.99 Mn |
| Dec 31, 2023 | -20.96 Mn |
| Sep 30, 2023 | -14.63 Mn |